Today: Today, Parexel International Corp. (PRXL) Price Target Cut to $64.00

Today, Parexel International Corp. (PRXL) Price Target Cut to $64.00

Parexel International Corp. (NASDAQ:PRXL) had its price objective dropped by research analysts at Jefferies Group from $67.00 to $64.00 in a research note issued on Wednesday. The brokerage presently has a “hold” rating on the stock. Jefferies Group’s price objective indicates a potential upside of 10.04% from the company’s previous close.

Several other research firms also recently commented on PRXL. Evercore ISI reissued a “buy” rating and issued a $70.00 price objective (down previously from $79.00) on shares of Parexel International Corp. in a report on Saturday, October 29th. Credit Suisse Group AG reissued a “buy” rating on shares of Parexel International Corp. in a report on Wednesday, November 16th. Citigroup Inc. increased their price objective on Parexel International Corp. from $74.00 to $80.00 and gave the company a “buy” rating in a report on Friday, August 5th. First Analysis downgraded Parexel International Corp. from an “overweight” rating to an “equal weight” rating and set a $62.00 price objective for the company. in a report on Thursday, November 17th. Finally, Zacks Investment Research raised Parexel International Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, October 19th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $66.70.

Shares of Parexel International Corp. (NASDAQ:PRXL) opened at 58.16 on Wednesday. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of 18.64 and a beta of 0.91. Parexel International Corp. has a one year low of $51.16 and a one year high of $71.13. The stock’s 50 day moving average price is $62.05 and its 200 day moving average price is $64.14.

Parexel International Corp. (NASDAQ:PRXL) last issued its quarterly earnings results on Wednesday, October 26th. The company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.86 by $0.10. The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $525.15 million. Parexel International Corp. had a return on equity of 30.71% and a net margin of 7.09%. Parexel International Corp.’s revenue was down 2.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 earnings per share. On average, equities analysts anticipate that Parexel International Corp. will post $3.75 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of PRXL. Dalton Greiner Hartman Maher & Co. boosted its position in Parexel International Corp. by 87.6% in the third quarter. Dalton Greiner Hartman Maher & Co. now owns 447,854 shares of the company’s stock valued at $31,103,000 after buying an additional 209,116 shares during the last quarter. Aristotle Capital Boston LLC boosted its position in Parexel International Corp. by 3.5% in the second quarter. Aristotle Capital Boston LLC now owns 156,770 shares of the company’s stock valued at $9,858,000 after buying an additional 5,298 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Parexel International Corp. by 4.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 86,769 shares of the company’s stock valued at $5,443,000 after buying an additional 3,389 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Parexel International Corp. by 1.2% in the second quarter. Dimensional Fund Advisors LP now owns 908,947 shares of the company’s stock valued at $57,150,000 after buying an additional 11,098 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Parexel International Corp. by 7.2% in the first quarter. Geode Capital Management LLC now owns 404,974 shares of the company’s stock valued at $25,404,000 after buying an additional 27,205 shares during the last quarter. Hedge funds and other institutional investors own 96.13% of the company’s stock.

About Parexel International Corp.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

Receive News & Ratings for Parexel International Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Parexel International Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment